

Raymond Evers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11428872/publications.pdf>

Version: 2024-02-01

55
papers

9,327
citations

101543

36
h-index

161849

54
g-index

58
all docs

58
docs citations

58
times ranked

8115
citing authors

#	ARTICLE	IF	CITATIONS
1	Membrane transporters in drug development. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 215-236.	46.4	2,886
2	A Family of Drug Transporters: the Multidrug Resistance-Associated Proteins. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1295-1302.	6.3	1,579
3	The multidrug resistance protein family. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1999, 1461, 347-357.	2.6	550
4	Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. <i>Nature Medicine</i> , 1997, 3, 1275-1279.	30.7	409
5	Interactions of the Human Multidrug Resistance Proteins MRP1 and MRP2 with Organic Anions. <i>Molecular Pharmacology</i> , 2000, 57, 760-768.	2.3	299
6	Functional Multidrug Resistance Protein (MRP1) Lacking the N-terminal Transmembrane Domain. <i>Journal of Biological Chemistry</i> , 1998, 273, 32167-32175.	3.4	283
7	Species differences in drug transporters and implications for translating preclinical findings to humans. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 237-252.	3.3	239
8	Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. <i>Biochemical Journal</i> , 1999, 338, 393-401.	3.7	232
9	Interindividual Variability in Hepatic Organic Anion-Transporting Polypeptides and P-Glycoprotein (ABCB1) Protein Expression: Quantification by Liquid Chromatography Tandem Mass Spectroscopy and Influence of Genotype, Age, and Sex. <i>Drug Metabolism and Disposition</i> , 2014, 42, 78-88.	3.3	169
10	Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 673-683.	2.5	158
11	In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1339-1354.	3.3	152
12	Interspecies Variability in Expression of Hepatobiliary Transporters across Human, Dog, Monkey, and Rat as Determined by Quantitative Proteomics. <i>Drug Metabolism and Disposition</i> , 2015, 43, 367-374.	3.3	152
13	Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide <scp>1B</scp> clinical probe than rosuvastatin. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 587-598.	2.4	138
14	Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. <i>FEBS Letters</i> , 1997, 419, 112-116.	2.8	130
15	Characterization of Mice Lacking the Multidrug Resistance Protein Mrp2 (Abcc2). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 579-589.	2.5	129
16	<i>Trypanosoma brucei</i> contains two RNA polymerase II largest subunit genes with an altered C-terminal domain. <i>Cell</i> , 1989, 56, 585-597.	28.9	125
17	Establishment of a Hepatocyte-Kupffer Cell Coculture Model for Assessment of Proinflammatory Cytokine Effects on Metabolizing Enzymes and Drug Transporters. <i>Drug Metabolism and Disposition</i> , 2015, 43, 774-785.	3.3	113
18	Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1752-1758.	3.3	100

#	ARTICLE	IF	CITATIONS
19	Transport of Ethinylestradiol Glucuronide and Ethinylestradiol Sulfate by the Multidrug Resistance Proteins MRP1, MRP2, and MRP3. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 309, 156-164.	2.5	98
20	Comparison of Immortalized Fa2N-4 Cells and Human Hepatocytes as in Vitro Models for Cytochrome P450 Induction. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1046-1055.	3.3	91
21	Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 900-915.	4.7	91
22	The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist?. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1498-1509.	3.3	82
23	Activators of the Rat Pregnane X Receptor Differentially Modulate Hepatic and Intestinal Gene Expression. <i>Molecular Pharmacology</i> , 2004, 65, 1159-1171.	2.3	74
24	Critical Review of Preclinical Approaches to Investigate Cytochrome P450-Mediated Therapeutic Protein Drug-Drug Interactions and Recommendations for Best Practices: A White Paper. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1598-1609.	3.3	68
25	Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytes. <i>Nucleic Acids Research</i> , 2009, 37, 1160-1173.	14.5	67
26	Role of the N-terminal Transmembrane Region of the Multidrug Resistance Protein MRP2 in Routing to the Apical Membrane in MDCKII Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 31048-31055.	3.4	65
27	Interindividual and Regional Variability in Drug Transporter Abundance at the Human Blood-Brain Barrier Measured by Quantitative Targeted Proteomics. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 228-237.	4.7	64
28	Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2357-2367.	3.3	59
29	Transport of the glutathione conjugate of ethacrynic acid by the human multidrug resistance protein MRP. <i>FEBS Letters</i> , 1996, 391, 126-130.	2.8	55
30	Evaluation of Cynomolgus Monkeys for the Identification of Endogenous Biomarkers for Hepatic Transporter Inhibition and as a Translatable Model to Predict Pharmacokinetic Interactions with Statins in Humans. <i>Drug Metabolism and Disposition</i> , 2015, 43, 851-863.	3.3	55
31	In Vitro Assessment of Drug-Drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters. <i>Drug Metabolism and Disposition</i> , 2013, 41, 668-681.	3.3	50
32	Characterization of Multidrug Resistance 1a/P-Glycoprotein Knockout Rats Generated by Zinc Finger Nucleases. <i>Molecular Pharmacology</i> , 2012, 81, 220-227.	2.3	48
33	Quantitative Transporter Proteomics by Liquid Chromatography with Tandem Mass Spectrometry: Addressing Methodologic Issues of Plasma Membrane Isolation and Expression-Activity Relationship. <i>Drug Metabolism and Disposition</i> , 2015, 43, 284-288.	3.3	44
34	Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics. <i>Drug Metabolism and Disposition</i> , 2018, 46, 189-196.	3.3	43
35	Role of the Murine Organic Anion-Transporting Polypeptide 1b2 (Oatp1b2) in Drug Disposition and Hepatotoxicity: Fig. 1.. <i>Molecular Pharmacology</i> , 2008, 74, 309-311.	2.3	38
36	Evaluation of Organic Anion Transporting Polypeptide 1B1 and 1B3 Humanized Mice as a Translational Model to Study the Pharmacokinetics of Statins. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1301-1313.	3.3	31

#	ARTICLE	IF	CITATIONS
37	A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 403-415.	4.7	31
38	Determining P-glycoprotein drug interactions: Evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers. <i>Journal of Pharmacological and Toxicological Methods</i> , 2012, 65, 64-74.	0.7	30
39	The Trypanosoma brucei protein phosphatase gene: polycistronic transcription with the RNA polymerase II largest subunit gene. <i>Nucleic Acids Research</i> , 1990, 18, 5089-5095.	14.5	29
40	Identification of potential pharmacological and toxicological targets differentiating structural analogs by a combination of transcriptional profiling and promoter analysis in LS-180 and Caco-2 adenocarcinoma cell lines. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 579-599.	1.5	29
41	Application of a Rat Liver Drug Bioactivation Transcriptional Response Assay Early in Drug Development That Informs Chemically Reactive Metabolite Formation and Potential for Drug-induced Liver Injury. <i>Toxicological Sciences</i> , 2020, 177, 281-299.	3.1	27
42	Unusual C-terminal domain of the largest subunit of RNA polymerase II of Crithidia fasciculata. <i>Nucleic Acids Research</i> , 1989, 17, 3403-3413.	14.5	26
43	Regulation of Drug Transport Proteins From Mechanisms to Clinical Impact: A White Paper on Behalf of the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 461-484.	4.7	26
44	Metabolism and Renal Elimination of Gaboxadol in Humans: Role of UDP-Glucuronosyltransferases and Transporters. <i>Pharmaceutical Research</i> , 2009, 26, 459-468.	3.5	18
45	Antibiotic-induced Elevations of Plasma Bile Acids in Rats Independent of Bsep Inhibition. <i>Toxicological Sciences</i> , 2017, 157, kfx015.	3.1	13
46	Comments on Mougey et al. (2009). <i>Pharmacogenetics and Genomics</i> , 2012, 22, 319-322.	1.5	12
47	A Two-Tiered In Vitro Approach to De-Risk Drug Candidates for Potential Bile Salt Export Pump Inhibition Liabilities in Drug Discovery. <i>Drug Metabolism and Disposition</i> , 2020, 48, 1147-1160.	3.3	12
48	Phylogenetic analysis of the RNA polymerases of Trypanosoma brucei, with special reference to class-specific transcription. <i>Current Genetics</i> , 1990, 18, 547-551.	1.7	8
49	Use of a Bile Salt Export Pump Knockdown Rat Susceptibility Model to Interrogate Mechanism of Drug-Induced Liver Toxicity. <i>Toxicological Sciences</i> , 2019, 170, 180-198.	3.1	7
50	Assessment of Pharmacokinetic Interaction Between Gefapixant (MK-2264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 406-412.	1.6	6
51	Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG. <i>Pharmacogenomics</i> , 2016, 17, 615-631.	1.3	4
52	Chapter 31. Enzyme induction Mechanisms, assays, and relevance to drug discovery and development. <i>Annual Reports in Medicinal Chemistry</i> , 2003, 38, 315-331.	0.9	2
53	In Vitro Techniques to Study Transporter-Based DDI. , 2010, , 237-255.		1
54	Protein drug-drug interactions for therapeutic modalities. , 2020, , 387-416.		1

#	ARTICLE	IF	CITATIONS
55	Transporter expression in non-cancerous and cancerous liver tissue from subjects with hepatocellular carcinoma and chronic hepatitis C infection quantified by LC-MS/MS proteomics. Drug Metabolism and Pharmacokinetics, 2018, 33, S18-S19.	2.2	0